Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

NCT06300424 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
EGFR Gene Mutation

Interventions

DRUG: almonertinib
DRUG: Carboplatin
DRUG: Nab paclitaxel

Sponsor

Guangdong Provincial People's Hospital